Insulin analogues: Action profiles beyond glycaemic control

References

• Anderson J H, Jr., Brunelle R L, Koivisto V A, Pfutzner A, Trautmann M E, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265–270
   PubMed Web of Science ®Google Scholar
• Barnett A H. How well do rapid-acting insulins work in obese individuals. Diabetes Obes Metab 2006; 8: 388–395
   PubMed Web of Science ®Google Scholar
• Becker R H, Frick A D, Burger F, Potgieter J H, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113: 435–443
   PubMed Web of Science ®Google Scholar
• Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring H U. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 1998; 30: 123–129
   PubMed Web of Science ®Google Scholar
• Bornfeldt K E, Gidlof R A, Wasteson A, Lake M, Skottner A, Arnqvist H J. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307–313
   Google Scholar
• Boskovic R, Feig D S, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003; 26: 1390–1394
   PubMed Web of Science ®Google Scholar
• Brunelle B L, Llewelyn J, Anderson J H, Jr., Gale E A, Koivisto V A. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726–1731
   PubMed Web of Science ®Google Scholar
• Bruning J C, Gautam D, Burks D J, Gillette J, Schubert M, Orban P C, Klein R, Krone W, Muller-Wieland D, Kahn C R. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122–2125
   PubMed Web of Science ®Google Scholar
• Brunner G A, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs G J, Pieber T R. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000a; 17: 371–375
   PubMed Web of Science ®Google Scholar
• Brunner G A, Sendhofer G, Wutte A, Ellmerer M, Sogaard B, Siebenhofer A, Hirschberger S, Krejs G J, Pieber T R. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000b; 108: 100–105
   PubMed Web of Science ®Google Scholar
• Brunton S A. Nocturnal Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs. MedGenMed 2007; 9: 38
   PubMedGoogle Scholar
• Calle-Pascual A L, Bagazgoitia J, Calle J R, Charro A, Maranes J P. Use of insulin lispro in pregnancy. Diabetes Nutr Metab 2000; 13: 173–177
   PubMedGoogle Scholar
• Chapman T M, Perry C M. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs 2005; 19: 67–69
   PubMed Web of Science ®Google Scholar
• Ciaraldi T P, Carter L, Seipke G, Mudaliar S, Henry R R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001; 86: 5838–5847
   PubMed Web of Science ®Google Scholar
• Ciaraldi T P, Phillips S A, Carter L, Aroda V, Mudaliar S, Henry R R. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: Comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab 2005; 90: 5551–5558
   PubMed Web of Science ®Google Scholar
• Dailey G, Rosenstock J, Moses R G, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363–2368
   PubMed Web of Science ®Google Scholar
• Di Cianni G, Volpe L, Ghio A, Lencioni C, Cuccuru I, Benzi L, Del Prato S. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care 2007; 30: e11
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke H J, Honka M, Ackermann R W, Merilainen M, Gallwitz B, Sreenan S, Group O B. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2007; 24: 369–376
   Web of Science ®Google Scholar
• Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259–285
   PubMed Web of Science ®Google Scholar
• Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702–707
   PubMed Web of Science ®Google Scholar
• Duckworth W, Davis S N. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications 2007; 21: 196–204
   PubMed Web of Science ®Google Scholar
• Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007; 50: 2534–2543
   PubMed Web of Science ®Google Scholar
• Eckel J. Insulin analogs revisited. Current Medicinal Chemistry – Immunology, Endocrine & Metabolic Agents. 2005; 5: 475–484
   Google Scholar
• Ellmerer M, Schaupp L, Brunner G A, Sendlhofer G, Wutte A, Wach P, Pieber T R. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol Endocrinol Metab 2000; 278: E352–E356
   PubMed Web of Science ®Google Scholar
• Fulcher G R, Gilbert R E, Yue D K. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35: 536–542
   PubMed Web of Science ®Google Scholar
• Galloway J A, Chance R E. Improving insulin therapy: achievements and challenges. Horm Metab Res 1994; 26: 591–598
   PubMed Web of Science ®Google Scholar
• Garg S K, Anderson J H, Gerard L A, Mackenzie T A, Gottlieb P A, Jennings M K, Chase H P. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obes Metab 2000; 2: 307–311
   PubMed Web of Science ®Google Scholar
• Garg S K, Frias J P, Anil S, Gottlieb P A, MacKenzie T, Jackson W E. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract 2003; 9: 187–193
   PubMedGoogle Scholar
• Garg S K, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract 2005; 11: 11–17
   PubMedGoogle Scholar
• Gerich J, Becker R H, Zhu R, Bolli G B. Fluctuation of serum Basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 2006; 8: 237–243
   PubMed Web of Science ®Google Scholar
• Griffen S C, Oostema K, Stanhope K L, Graham J, Styne D M, Glaser N, Cummings D E, Connors M H, Havel P J. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab 2006; 91: 485–491
   PubMed Web of Science ®Google Scholar
• Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498–1504
   PubMed Web of Science ®Google Scholar
• Haycox A. Insulin aspart: an evidence-based medicine review. Clin Drug Investig 2004; 24: 695–717
   PubMed Web of Science ®Google Scholar
• Hedman C A, Lindstrom T, Arnqvist H J. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 2001; 24: 1120–1121
   PubMed Web of Science ®Google Scholar
• Heinemann L, Starke A A, Hohmann A, Berger M. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res 1992; Suppl 26: 137–139
   Web of Science ®Google Scholar
• Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick A D, Becker R H. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746–753
   PubMed Web of Science ®Google Scholar
• Heller S R, Amiel S A, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999; 22: 1607–1611
   PubMed Web of Science ®Google Scholar
• Hennige A M, Lehmann R, Weigert C, Moeschel K, Schauble M, Metzinger E, Lammers R, Haring H U. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 2005a; 54: 361–366
   PubMed Web of Science ®Google Scholar
• Hennige A M, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Haring H U. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274–1282
   PubMed Web of Science ®Google Scholar
• Hennige A M, Strack V, Metzinger E, Seipke G, Haring H U, Kellerer M. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 2005b; 48: 1891–1897
   PubMed Web of Science ®Google Scholar
• Hod M, Damm P, Kaaja R, Visser G H, Dunne F, Demidova I, Hansen A S, Mersebach H. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2007; 198: 186.e1–186.e7
   PubMedGoogle Scholar
• Holcberg G, Tsadkin-Tamir M, Sapir O, Wiznizer A, Segal D, Polachek H, Ben Zvi Z. Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol 2004; 115: 117–118
   PubMed Web of Science ®Google Scholar
• Homko C, Deluzio A, Jimenez C, Kolaczynski J W, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027–2031
   PubMed Web of Science ®Google Scholar
• Homko C J, Reece E A. Insulins and oral hypoglycemic agents in pregnancy. J Matern Fetal Neonatal Med 2006; 19: 679–686
   PubMed Web of Science ®Google Scholar
• Hordern S V, Wright J E, Umpleby A M, Shojaee-Moradie F, Amiss J, Russell-Jones D L. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420–426
   PubMed Web of Science ®Google Scholar
• Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402
   Google Scholar
• Kacerovsky-Bielesz G, Dressler A, Freunscht R. Long-term glycaemic control with insulin glargine in Type 2 diabetes. Diabetes Res Clin Pract 2005; 71: 184–191
   PubMed Web of Science ®Google Scholar
• Kaiyala K J, Prigeon R L, Kahn S E, Woods S C, Schwartz M W. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000; 49: 1525–1533
   PubMed Web of Science ®Google Scholar
• Knott G W, Dziegielewska K M, Habgood M D, Li Z S, Saunders N R. Albumin transfer across the choroid plexus of South American opossum (Monodelphis domestica). J Physiol 1997; 499(1)179–194
   PubMed Web of Science ®Google Scholar
• Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: The evidence from Germany – the CoDiM study. Diabetologia 2006; 49: 1498–1504
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli G B. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148
   PubMed Web of Science ®Google Scholar
• Lindholm A, McEwen J, Riis A P. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801–805
   PubMed Web of Science ®Google Scholar
• Lingohr M K, Dickson L M, McCuaig J F, Hugl S R, Twardzik D R, Rhodes C J. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 2002; 51: 966–976
   PubMed Web of Science ®Google Scholar
• Luzio S, Peter R, Dunseath G J, Mustafa L, Owens D R. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Res Clin Pract 2007; 79: 269–275
   PubMed Web of Science ®Google Scholar
• Markussen J, Havelund S, Kurtzhals P, Andersen A S, Halstrom J, Hasselager E, Larsen U D, Ribel U, Schaffer L, Vad K, Jonassen I. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281–288
   PubMed Web of Science ®Google Scholar
• Mathiesen E R, Kinsley B, Amiel S A, Heller S, McCance D, Duran S, Bellaire S, Raben A. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771–776
   PubMed Web of Science ®Google Scholar
• Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber J P. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998; 21: 977–982
   PubMed Web of Science ®Google Scholar
• Murase Y, Yagi K, Sugihara M, Chujo D, Otsuji M, Muramoto H, Mabuchi H. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. Intern Med 2004; 43: 779–786
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: A randomized, stratified, double-blind and cross-over trial. Diabetic Medicine 2005; 22: 606–611
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann M E, Haslbeck M, Schatz H, Beyer J. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996; 104: 25–30
   PubMed Web of Science ®Google Scholar
• Pieber T R, Treichel H C, Hompesch B, Philotheou A, Mordhorst L, Gall M A, Robertson L I. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635–642
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl L A, Draeger E, Zdravkovic M, Pieber T R. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107–1112
   PubMed Web of Science ®Google Scholar
• Porte D., Jr. Central regulation of energy homeostasis: the key role of insulin. Diabetes 55 Suppl 2 2006; S155–S160
   Google Scholar
• Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003a; 52: 2227–2238
   PubMed Web of Science ®Google Scholar
• Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action. Biochem Biophys Res Commun 2003b; 310: 852–859
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, Halle J P, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666–1671
   PubMed Web of Science ®Google Scholar
• Raslova K, Tamer S C, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279–285
   PubMed Web of Science ®Google Scholar
• Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999; 22: 784–788
   PubMed Web of Science ®Google Scholar
• Rhodes C J. Type 2 diabetes – a matter of beta-cell life and death. Science 2005; 307: 380–384
   PubMed Web of Science ®Google Scholar
• Riddle M C, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–3086
   PubMed Web of Science ®Google Scholar
• Rosenfalck A M, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen K F, Madsbad S. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41–46
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23: 1137–1142
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz S L, Clark C M, Jr., Park G D, Donley D W, Edwards M B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631–636
   PubMed Web of Science ®Google Scholar
• Rossetti P, Porcellati F, Busciantella R N, Candeloro P, Cioli P, Bolli G B, Fanelli G G. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2007; 57: 746–756
   PubMed Web of Science ®Google Scholar
• Schwartz M W, Woods S C, Porte D, Jr., Seeley R J, Baskin D G. Central nervous system control of food intake. Nature 2000; 404: 661–771
   PubMed Web of Science ®Google Scholar
• Seyfert S, Kunzmann V, Schwertfeger N, Koch H C, Faulstich A. Determinants of lumbar CSF protein concentration. J Neurol 2002; 249: 1021–1026
   PubMed Web of Science ®Google Scholar
• Shymko R M, Dumont E, De Meyts P, Dumont J E. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 1999; 339(3)675–683
   PubMedGoogle Scholar
• Slieker L J, Brooke G S, DiMarchi R D, Flora D B, Green L K, Hoffmann J A, Long H B, Fan L, Shields J E, Sundell K L, Surface P L, Chance R E. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40: S54–S61
   PubMed Web of Science ®Google Scholar
• Staiger K, Staiger H, Schweitzer M A, Metzinger E, Balletshofer B, Haring H U, Kellerer M. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48: 1898–1905
   PubMed Web of Science ®Google Scholar
• Stammberger I, Seipke G, Bartels T. Insulin glulisine-a comprehensive preclinical evaluation. Int J Toxicol 2006; 25: 25–33
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986
   PubMed Web of Science ®Google Scholar
• Tibaldi J. Actions of insulin beyond glycemic control: A perspective on insulin detemir. Adv Ther 2007; 24: 868–882
   PubMed Web of Science ®Google Scholar
• Torlone E, Fanelli C, Rambotti A M, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713–720
   PubMed Web of Science ®Google Scholar
• Tschritter O, Hennige A M, Preissl H, Porubska K, Schafer S A, Lutzenberger W, Machicao F, Birbaumer N, Fritsche A, Haring H U. Cerebrocortical Beta activity in overweight humans responds to insulin detemir. PLoS ONE 2007; 2: e1196
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837–853
   PubMed Web of Science ®Google Scholar
• Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001; 22: 706–717
   PubMed Web of Science ®Google Scholar
• White M F. The insulin signalling system and the IRS proteins. Diabetologia 1997; 40: S2–17
   PubMed Web of Science ®Google Scholar
• Woods S C, Seeley R J, Baskin D G, Schwartz M W. Insulin and the blood-brain barrier. Curr Pharm Des 2003; 9: 795–800
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetesHOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130–1136
   PubMed Web of Science ®Google Scholar